December 21, 2021
2 min watch
Save
VIDEO: Treating advanced myelofibrosis with LSD1 inhibitor
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Aaron T. Gerds, MD, MS, highlighted findings from a study presented at ASH Annual Meeting and Exposition that explored treating advanced myelofibrosis using the LSD1 inhibitor bomedemstat.
“If we’re able to change the clonal landscape, and clonal structure, back to an earlier form, it would be like resetting a clock for these patients with their disease,” said Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute and medical director of Case Comprehensive Cancer Center.
Reference
- Gill H, et al. Abstract 139. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gerds reports consulting for AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, Novartis, PharmaEssentia and Sierra Oncology; and providing research support for Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation and Kratos Pharmaceuticals.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.